[{"id":"3sbio","name":"3SBio","tldr":"3SBio is a Shenyang biologics company whose HER2 antibody inetetamab was approved in China in 2020 for HER2-positive metastatic breast cancer.","route":"/companies/3sbio/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=3sbio.com&sz=128","avatar":"org","sub":"Shenyang, China, CN","facets":{"kind":["Company"],"cancers":["HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"adebrelimab","name":"Adebrelimab","tldr":"Adebrelimab is Hengrui's PD-L1 antibody, approved in China for first-line extensive-stage small cell lung cancer on the CAPSTONE-1 trial.","route":"/drugs/adebrelimab/","status":"approved","kind":"drug","molecule":"adebrelimab","modality":"Monoclonal antibody (anti-PD-L1, humanised IgG4)","sub":"Arelili · SHR-1316","facets":{"kind":["Treatment"],"cancers":["Small-cell lung cancer","Extensive-stage small-cell lung cancer"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"year":{"facet":"year","value":"2023"},"tags":[]},"sortKeys":{"year":2023}},{"id":"aeneas","name":"AENEAS","tldr":"The trial that showed Hansoh's aumolertinib roughly doubles progression-free survival compared with gefitinib in EGFR-mutant lung cancer.","route":"/trials/aeneas/","status":"positive","kind":"trial","cancerIcon":"nsclc","sub":"NCT03849768","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"alphamab","name":"Alphamab Oncology","tldr":"Alphamab developed envafolimab, the first subcutaneous PD-L1 antibody approved anywhere, and the HER2 bispecific ADC JSKN003.","route":"/companies/alphamab/","kind":"company","logo":"/logos/alphamab.png","avatar":"org","sub":"Suzhou, CN · 9966.HK","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"alter-0303","name":"ALTER 0303","tldr":"The trial that showed anlotinib helps patients with lung cancer live longer after other treatments have failed, the basis of one of China's most used cancer pills.","route":"/trials/alter-0303/","status":"positive","kind":"trial","cancerIcon":"nsclc","sub":"NCT02388919","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":["2018"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2018"},"tags":[]},"sortKeys":{"year":2018}},{"id":"anlotinib","name":"Anlotinib","tldr":"Anlotinib is one of the most used cancer pills in China, first approved for lung cancer after other treatments have failed and then for several rarer tumours.","route":"/drugs/anlotinib/","status":"approved","kind":"drug","molecule":"anlotinib","modality":"Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, KIT)","sub":"Focus V · AL3818","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer","Sarcomas","Alveolar soft part sarcoma","Thyroid cancer"],"year":["2018"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."},{"label":"Alveolar soft part sarcoma","href":"/cancers/alveolar-soft-part-sarcoma/","tip":"Alveolar soft part sarcoma is a rare, slow-growing cancer of young adults driven by a single fusion gene, ASPSCR1-TFE3, that switches on blood vessel growth. Chemotherapy does not work, but drugs that block the tumour's blood supply shrink it, and in 2023 the immunotherapy atezolizumab became the first drug approved for it."}],"year":{"facet":"year","value":"2018"},"tags":[]},"sortKeys":{"year":2018}},{"id":"aumolertinib","name":"Aumolertinib","tldr":"Aumolertinib is Hansoh's third-generation lung cancer pill, the first China-developed drug of its class, approved for first-line EGFR-mutant lung cancer on the AENEAS trial.","route":"/drugs/aumolertinib/","status":"approved","kind":"drug","molecule":"aumolertinib","modality":"Small-molecule third-generation EGFR TKI","sub":"Ameile · HS-10296, almonertinib","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":["2020"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2020"},"tags":[]},"sortKeys":{"year":2020}},{"id":"beijing-gene-key-life-technology","name":"Beijing Gene Key Life Technology","tldr":"Beijing Gene Key Life Technology is a Chinese developer in Beijing that sponsors 2 registered cancer trials of GKL-006.","route":"/companies/beijing-gene-key-life-technology/","kind":"company","avatar":"org","sub":"Beijing, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"beijing-konruns-pharmaceutical","name":"Beijing Konruns Pharmaceutical","tldr":"Beijing Konruns Pharmaceutical is a Chinese developer in Beijing that sponsors 5 registered cancer trials of KC1036 and S-1.","route":"/companies/beijing-konruns-pharmaceutical/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=konruns.cn&sz=128","avatar":"org","sub":"Beijing, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"beijing-mabworks-biotech","name":"Beijing Mabworks Biotech","tldr":"Beijing Mabworks Biotech is a Chinese developer in Beijing that sponsors 4 registered cancer trials of MBS314 and MBS303.","route":"/companies/beijing-mabworks-biotech/","kind":"company","avatar":"org","sub":"Beijing, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"beijing-pearl-biotechnology-limited-liability-company","name":"Beijing Pearl Biotechnology Limited Liability Company","tldr":"Beijing Pearl Biotechnology Limited Liability Company is a Chinese developer in Beijing that sponsors 3 registered cancer trials of PLB1001 and Temozolomide.","route":"/companies/beijing-pearl-biotechnology-limited-liability-company/","kind":"company","avatar":"org","sub":"Beijing, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"beijing-scitech-mq-pharmaceuticals","name":"Beijing Scitech-Mq Pharmaceuticals","tldr":"Beijing Scitech-Mq Pharmaceuticals is a Chinese developer in Beijing that sponsors 3 registered cancer trials of ST-1898.","route":"/companies/beijing-scitech-mq-pharmaceuticals/","kind":"company","avatar":"org","sub":"Beijing, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"beijing-tide-pharmaceutical","name":"Beijing Tide Pharmaceutical","tldr":"Beijing Tide Pharmaceutical is a Chinese developer in Beijing that sponsors 2 registered cancer trials of TCC1727.","route":"/companies/beijing-tide-pharmaceutical/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=tidepharm.com&sz=128","avatar":"org","sub":"Beijing, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"benmelstobart","name":"Benmelstobart","tldr":"Benmelstobart is Chia Tai Tianqing's PD-L1 antibody, approved in China in 2024 for extensive-stage small-cell lung cancer in combination with anlotinib and chemotherapy.","route":"/drugs/benmelstobart/","status":"approved","kind":"drug","molecule":"benmelstobart","modality":"Anti-PD-L1 monoclonal antibody","sub":"TQB2450","facets":{"kind":["Treatment"],"cancers":["Small-cell lung cancer","Extensive-stage small-cell lung cancer"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."},{"label":"Extensive-stage small-cell lung cancer","href":"/cancers/extensive-stage-sclc/","tip":"Small-cell lung cancer that has spread responds fast to chemotherapy but almost always returns within a year. Adding an immunotherapy antibody to first-line chemotherapy helps a minority live for years, and the T-cell engager tarlatamab, which points immune cells at the DLL3 protein on the cancer, has for the first time lengthened life after relapse."}],"year":{"facet":"year","value":"2024"},"tags":[{"label":"nmpa-approved","href":"/tagged/nmpa-approved/","tip":"Every record tagged nmpa-approved."}]},"sortKeys":{"year":2024}},{"id":"betta","name":"Betta Pharmaceuticals","tldr":"Betta made icotinib, the first cancer drug invented in China, and later ensartinib, the first Chinese ALK inhibitor to win FDA approval.","route":"/companies/betta/","kind":"company","logo":"/logos/betta.png","avatar":"org","sub":"Hangzhou, CN · 300558.SZ","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"binhui-biopharmaceutical","name":"Binhui Biopharmaceutical","tldr":"Binhui Biopharmaceutical is a Chinese developer in Wuhan that sponsors 4 registered cancer trials of OH2 and HX008.","route":"/companies/binhui-biopharmaceutical/","kind":"company","avatar":"org","sub":"Wuhan, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"biostar-pharmaceuticals","name":"Biostar Pharmaceuticals","tldr":"Biostar Pharmaceuticals in Chengdu developed utidelone, the epothilone chemotherapy approved in China in 2021 for advanced breast cancer.","route":"/companies/biostar-pharmaceuticals/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=biostar.com.cn&sz=128","avatar":"org","sub":"Chengdu, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"camel","name":"CameL","tldr":"The trial that made camrelizumab a first-line lung cancer option in China, one of several domestic PD-1 antibodies to reproduce the KEYNOTE-189 result.","route":"/trials/camel/","status":"positive","kind":"trial","cancerIcon":"nsclc","sub":"NCT03134872","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"capstone-1","name":"CAPSTONE-1","tldr":"The trial that added Hengrui's PD-L1 antibody adebrelimab to chemotherapy for small cell lung cancer, with one of the larger survival gains seen in that disease.","route":"/trials/capstone-1/","status":"positive","kind":"trial","cancerIcon":"sclc","sub":"NCT03711305","facets":{"kind":["Trial"],"cancers":["Small-cell lung cancer"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"chengdu-zenitar-biomedical-technology","name":"Chengdu Zenitar Biomedical Technology","tldr":"Chengdu Zenitar Biomedical Technology is a Chinese developer in Chengdu that sponsors 6 registered cancer trials of Purinostat and Purinostat Mesylate.","route":"/companies/chengdu-zenitar-biomedical-technology/","kind":"company","avatar":"org","sub":"Chengdu, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"caca","name":"China Anti-Cancer Association","tldr":"The China Anti-Cancer Association is the country's largest cancer society, publishing the CACA guidelines that aim to reflect Chinese patients and Chinese drugs rather than imported recommendations.","route":"/institutions/caca/","kind":"institution","logo":"https://www.google.com/s2/favicons?domain=caca.org.cn&sz=128","avatar":"org","sub":"Tianjin, CN","facets":{"kind":["Institution"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Institution","tip":"The centres and universities that matter, mapped and ranked."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"ctong","name":"Chinese Thoracic Oncology Group","tldr":"CTONG is the cooperative group of Chinese lung cancer trialists, founded by Yi-Long Wu, whose trials on EGFR-targeted pills before and after surgery changed practice worldwide.","route":"/institutions/ctong/","kind":"institution","logo":"https://www.google.com/s2/favicons?domain=ctong.org.cn&sz=128","avatar":"org","sub":"Guangzhou, CN","facets":{"kind":["Institution"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Institution","tip":"The centres and universities that matter, mapped and ranked."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"chipscreen","name":"Chipscreen Biosciences","tldr":"Chipscreen discovered chidamide (tucidinostat), the first original epigenetic cancer drug from China, approved in 2014 and later in Japan.","route":"/companies/chipscreen/","kind":"company","logo":"/logos/chipscreen.png","avatar":"org","sub":"Shenzhen, CN · 688321.SS","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"chongqing-university-cancer-hospital","name":"Chongqing University Cancer Hospital","tldr":"Chongqing University Cancer Hospital is the main cancer centre for south-west China's largest city and a growing site for domestic trials.","route":"/institutions/chongqing-university-cancer-hospital/","kind":"institution","logo":"https://www.google.com/s2/favicons?domain=cqch.cn&sz=128","avatar":"org","sub":"Chongqing University · Chongqing, CN","facets":{"kind":["Institution"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Institution","tip":"The centres and universities that matter, mapped and ranked."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"cspc","name":"CSPC Pharmaceutical Group","tldr":"CSPC is a large Chinese pharma whose cancer business rests on albumin-bound paclitaxel and liposomal doxorubicin generics, an ADC pipeline and a growing list of licences to Western companies.","route":"/companies/cspc/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=cspc.com.hk&sz=128","avatar":"org","sub":"Shijiazhuang, CN · 1093.HK","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"cstone","name":"CStone Pharmaceuticals","tldr":"CStone developed sugemalimab, the first Chinese PD-L1 antibody approved in Europe, and brought pralsetinib, avapritinib and ivosidenib to China.","route":"/companies/cstone/","kind":"company","logo":"/logos/cstone.png","avatar":"org","sub":"Suzhou / Shanghai, CN · 2616.HK","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"dalpiciclib","name":"Dalpiciclib","tldr":"Dalpiciclib is Hengrui's CDK4/6 inhibitor, the first China-developed drug of the class, approved for hormone-driven advanced breast cancer on the DAWNA trials.","route":"/drugs/dalpiciclib/","status":"approved","kind":"drug","molecule":"dalpiciclib","modality":"Small-molecule CDK4/6 inhibitor","sub":"Airuikang · SHR6390","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"dawna-1","name":"DAWNA-1","tldr":"The trial that made dalpiciclib the first Chinese CDK4/6 inhibitor approved, more than doubling the time before breast cancer grew when added to fulvestrant.","route":"/trials/dawna-1/","status":"positive","kind":"trial","cancerIcon":"breast-hr-positive","sub":"NCT03927456","facets":{"kind":["Trial"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"donafenib","name":"Donafenib","tldr":"Donafenib is a Chinese redesign of sorafenib that lived longer than the original in a head-to-head liver cancer trial and is approved in China as a first-line option.","route":"/drugs/donafenib/","status":"approved","kind":"drug","molecule":"donafenib","modality":"Small-molecule multi-kinase inhibitor (deuterated sorafenib)","sub":"Zepsun · CM4307","facets":{"kind":["Treatment"],"cancers":["Hepatocellular carcinoma","Thyroid cancer"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Thyroid cancer","href":"/cancers/thyroid/","tip":"Thyroid cancer is usually curable with surgery and radioactive iodine, the original theranostic. Rare aggressive forms respond to RET and BRAF inhibitors."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"envafolimab","name":"Envafolimab","tldr":"Envafolimab is the first PD-L1 antibody given as a quick injection under the skin rather than an infusion, approved in China for advanced tumours with mismatch-repair deficiency.","route":"/drugs/envafolimab/","status":"approved","kind":"drug","molecule":"envafolimab","modality":"Single-domain antibody (anti-PD-L1, subcutaneous)","sub":"Enweida · KN035","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer","Cancer of unknown primary"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely, yet most metastatic disease still depends on chemotherapy."},{"label":"Cancer of unknown primary","href":"/cancers/cancer-of-unknown-primary/","tip":"Cancer found already spread, where doctors cannot find where it started. Genomic profiling finds a drug target in about a third of cases and tumour-agnostic approvals apply directly; the rest still rely on general-purpose chemotherapy, which is what those tests are changing."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"equecabtagene-autoleucel","name":"Equecabtagene autoleucel","tldr":"Equecabtagene autoleucel is a BCMA CAR-T from IASO Bio and Innovent, approved in China in June 2023 for multiple myeloma that has returned after at least three lines of treatment. In the FUMANBA-1 trial about 96% of infused patients responded, most with deep minimal-residual-disease-negative remissions and few severe cytokine release reactions; it competes with cilta-cel and zevor-cel in China.","route":"/drugs/equecabtagene-autoleucel/","status":"approved","kind":"drug","molecule":"equecabtagene-autoleucel","modality":"Cell therapy (autologous BCMA CAR-T, fully human binder)","sub":"Fucaso · eque-cel, CT103A","facets":{"kind":["Treatment"],"cancers":["Multiple myeloma"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"year":{"facet":"year","value":"2023"},"tags":[]},"sortKeys":{"year":2023}},{"id":"zhang-fangliang","name":"Fangliang (Frank) Zhang","tldr":"Frank Zhang founded GenScript and its cell therapy spin-out Legend Biotech, whose Nanjing team invented the myeloma CAR-T that became Carvykti.","route":"/people/zhang-fangliang/","kind":"person","round":true,"avatar":"person","sub":"Founder and former Chairman, Legend Biotech; former Chairman, GenScript Biotech","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"flumatinib","name":"Flumatinib","tldr":"Flumatinib is Hansoh Pharma's second-generation BCR-ABL inhibitor, approved in China in 2019 for newly diagnosed chronic-phase chronic myeloid leukaemia.","route":"/drugs/flumatinib/","status":"approved","kind":"drug","molecule":"flumatinib","modality":"Oral second-generation BCR-ABL tyrosine kinase inhibitor","sub":"HH-GV-678","facets":{"kind":["Treatment"],"cancers":["Chronic myeloid leukaemia"],"year":["2019"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Chronic myeloid leukaemia","href":"/cancers/cml/","tip":"Chronic myeloid leukaemia is a blood cancer driven by a single fused gene, BCR-ABL1, and the model for oncogene-targeted treatment: imatinib in 2001 and the tyrosine kinase inhibitors that followed turned it into a condition most people live with long-term. About half of patients with a sustained deep molecular response can now stop treatment altogether."}],"year":{"facet":"year","value":"2019"},"tags":[{"label":"nmpa-approved","href":"/tagged/nmpa-approved/","tip":"Every record tagged nmpa-approved."}]},"sortKeys":{"year":2019}},{"id":"fulzerasib","name":"Fulzerasib","tldr":"Fulzerasib was the first KRAS G12C-blocking pill approved in China, for lung cancers carrying that mutation after earlier treatment.","route":"/drugs/fulzerasib/","status":"approved","kind":"drug","molecule":"fulzerasib","modality":"Small-molecule covalent KRAS G12C inhibitor","sub":"Dupert · GFH925, IBI351","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"fumanba-1","name":"FUMANBA-1","tldr":"The single-arm trial that won eque-cel its approval in China, with almost every patient responding and most reaching deep remissions.","route":"/trials/fumanba-1/","status":"positive","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT05066646","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"furlong","name":"FURLONG","tldr":"The head-to-head trial in which furmonertinib nearly doubled the time before lung cancer grew compared with gefitinib, mirroring FLAURA with a Chinese drug.","route":"/trials/furlong/","status":"positive","kind":"trial","cancerIcon":"nsclc","sub":"NCT03787992","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"furmonertinib","name":"Furmonertinib","tldr":"Furmonertinib is a Chinese lung cancer pill of the same class as osimertinib, which more than doubled the time before cancer grew compared with gefitinib in the FURLONG trial.","route":"/drugs/furmonertinib/","status":"approved","kind":"drug","molecule":"furmonertinib","modality":"Small-molecule third-generation EGFR TKI","sub":"Ivesa · AST2818, alflutinib","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"EGFR-mutated non-small-cell lung cancer","href":"/cancers/egfr-mutant-nsclc/","tip":"EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"garsorasib","name":"Garsorasib","tldr":"Garsorasib is InventisBio's KRAS G12C-blocking pill, approved in China in 2024 for previously treated lung cancer with that mutation.","route":"/drugs/garsorasib/","status":"approved","kind":"drug","molecule":"garsorasib","modality":"Small-molecule covalent KRAS G12C inhibitor","sub":"D-1553","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","KRAS G12C-mutant non-small-cell lung cancer"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"KRAS G12C-mutant non-small-cell lung cancer","href":"/cancers/kras-g12c-nsclc/","tip":"KRAS G12C lung cancer carries a mutation that was thought impossible to drug for forty years. Sotorasib and adagrasib now shrink about four in ten tumours after chemotherapy and immunotherapy, though the benefit is measured in months, and newer inhibitors and first-line combinations with immunotherapy are in trials."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"li-ge","name":"Ge Li","tldr":"Ge Li founded WuXi AppTec in Shanghai in 2000 and built the contract research and manufacturing network that much of the world's cancer pipeline now depends on.","route":"/people/li-ge/","kind":"person","round":true,"avatar":"person","sub":"Founder, Chairman and CEO, WuXi AppTec","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"gemstone-302","name":"GEMSTONE-302","tldr":"The trial behind sugemalimab's approval in China and later Europe, showing a PD-L1 antibody plus chemotherapy delays progression in both main types of lung cancer.","route":"/trials/gemstone-302/","status":"positive","kind":"trial","cancerIcon":"nsclc","sub":"NCT03789604","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"genfleet","name":"GenFleet Therapeutics","tldr":"GenFleet discovered fulzerasib, the first KRAS G12C inhibitor approved in China, and licensed it to Innovent for the Chinese market.","route":"/companies/genfleet/","kind":"company","logo":"/logos/genfleet.png","avatar":"org","sub":"Shanghai, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"h101-oncolytic-adenovirus","name":"H101 oncolytic adenovirus","tldr":"Oncorine is Shanghai Sunway Biotech's oncolytic adenovirus, approved in China in 2005 for nasopharyngeal carcinoma with chemotherapy, the first oncolytic virus approved anywhere in the world.","route":"/drugs/h101-oncolytic-adenovirus/","status":"approved","kind":"drug","molecule":"h101-oncolytic-adenovirus","modality":"Oncolytic virus (E1B-deleted adenovirus)","sub":"H101","facets":{"kind":["Treatment"],"cancers":["Nasopharyngeal carcinoma"],"year":["2005"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Nasopharyngeal carcinoma","href":"/cancers/nasopharyngeal/","tip":"A cancer at the back of the nose caused largely by the Epstein-Barr virus and common in southern China and Southeast Asia. Radiation cures most early cases; adding chemotherapy and, recently, PD-1 immunotherapy has improved outcomes in advanced disease, and a blood test for viral DNA can detect it early."}],"year":{"facet":"year","value":"2005"},"tags":[{"label":"nmpa-approved","href":"/tagged/nmpa-approved/","tip":"Every record tagged nmpa-approved."}]},"sortKeys":{"year":2005}},{"id":"hansoh-pharma","name":"Hansoh Pharmaceutical","tldr":"Hansoh is a Chinese pharmaceutical group whose EGFR inhibitor aumolertinib (Ameile in China, Aumseqa in the EU) became the first China-originated lung cancer pill authorised by the European Commission in 2026.","route":"/companies/hansoh-pharma/","kind":"company","logo":"/logos/hansoh-pharma.svg","avatar":"org","sub":"Lianyungang, Jiangsu, CN · 3692.HK","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"harmoni-a","name":"HARMONi-A","tldr":"The first phase 3 win for ivonescimab, in lung cancer that has stopped responding to EGFR pills, and the basis of its first approval in China.","route":"/trials/harmoni-a/","status":"positive","kind":"trial","cancerIcon":"nsclc","sub":"NCT05184712","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"henan-genuine-biotech","name":"Henan Genuine Biotech","tldr":"Henan Genuine Biotech is a Chinese developer in Henan that sponsors 2 registered cancer trials of GEN-725 and Dositinib.","route":"/companies/henan-genuine-biotech/","kind":"company","logo":"/logos/henan-genuine-biotech.png","avatar":"org","sub":"Henan, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"hutchmed","name":"Hutchmed","tldr":"Hutchmed discovered fruquintinib, the first Chinese cancer drug approved by the FDA for a common cancer, and savolitinib, its MET inhibitor partnered with AstraZeneca.","route":"/companies/hutchmed/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=hutch-med.com&sz=128","avatar":"org","sub":"Hong Kong / Shanghai, CN · HCM / 13.HK","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"iaso-bio","name":"IASO Biotherapeutics","tldr":"IASO Bio developed eque-cel, the fully human BCMA CAR-T for myeloma approved in China in 2023 and partnered with Innovent.","route":"/companies/iaso-bio/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=iasobio.com&sz=128","avatar":"org","sub":"Nanjing / Shanghai, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"icotinib","name":"Icotinib","tldr":"Icotinib, approved in 2011, was the first cancer drug invented and developed in China, and it showed that a domestic lung cancer pill could match a Western one head to head.","route":"/drugs/icotinib/","status":"approved","kind":"drug","molecule":"icotinib","modality":"Small-molecule first-generation EGFR TKI","sub":"Conmana · BPI-2009H","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":["2011"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2011"},"tags":[]},"sortKeys":{"year":2011}},{"id":"immvira-pharma","name":"ImmVira Pharma","tldr":"ImmVira Pharma is a Chinese developer in Shenzhen that sponsors 3 registered cancer trials of Herpes Virus C5252 and T3011.","route":"/companies/immvira-pharma/","kind":"company","avatar":"org","sub":"Shenzhen, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"inaticabtagene-autoleucel","name":"Inaticabtagene autoleucel","tldr":"Inati-cel is a Chinese CAR-T for adults with acute lymphoblastic leukaemia that has come back or stopped responding, approved in 2023.","route":"/drugs/inaticabtagene-autoleucel/","status":"approved","kind":"drug","molecule":"inaticabtagene-autoleucel","modality":"Cell therapy (autologous CD19 CAR-T)","sub":"Yuanruida · inati-cel, CNCT19","facets":{"kind":["Treatment"],"cancers":["Acute lymphoblastic leukaemia"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"year":{"facet":"year","value":"2023"},"tags":[]},"sortKeys":{"year":2023}},{"id":"inetetamab","name":"Inetetamab","tldr":"Inetetamab is 3SBio's HER2 antibody, approved in China in 2020 with vinorelbine for HER2-positive metastatic breast cancer.","route":"/drugs/inetetamab/","status":"approved","kind":"drug","molecule":"inetetamab","modality":"Anti-HER2 monoclonal antibody, Fc-engineered","facets":{"kind":["Treatment"],"cancers":["HER2-positive breast cancer"],"year":["2020"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"year":{"facet":"year","value":"2020"},"tags":[{"label":"nmpa-approved","href":"/tagged/nmpa-approved/","tip":"Every record tagged nmpa-approved."}]},"sortKeys":{"year":2020}},{"id":"innocare","name":"InnoCare Pharma","tldr":"InnoCare developed orelabrutinib, a selective BTK-blocking pill approved in China for chronic lymphocytic leukaemia and mantle cell and marginal zone lymphomas.","route":"/companies/innocare/","kind":"company","logo":"/logos/innocare.png","avatar":"org","sub":"Beijing, CN · 9969.HK / 688428.SS","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"innovent","name":"Innovent Biologics","tldr":"Innovent makes sintilimab, China's best-selling PD-1 antibody, and has become a source of next-generation assets for Roche and Takeda.","route":"/companies/innovent/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=innoventbio.com&sz=128","avatar":"org","sub":"Suzhou, CN · 1801.HK","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"cams-hematology","name":"Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences","tldr":"China's national blood disease hospital in Tianjin is where the CD19 binder behind the CAR-T inati-cel was made; it runs large leukaemia and myelodysplastic syndrome registries and early-phase trials of domestic bispecifics and cell therapies.","route":"/institutions/cams-hematology/","kind":"institution","logo":"https://www.google.com/s2/favicons?domain=chinablood.com.cn&sz=128","avatar":"org","sub":"Chinese Academy of Medical Sciences and Peking Union Medical College · Tianjin, CN","facets":{"kind":["Institution"],"cancers":["Acute lymphoblastic leukaemia","Acute myeloid leukaemia","Myelodysplastic syndromes / neoplasms"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Institution","tip":"The centres and universities that matter, mapped and ranked."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Myelodysplastic syndromes / neoplasms","href":"/cancers/mds/","tip":"Bone-marrow disorders where blood cells are made badly and too few reach the blood; a third progress to acute leukaemia. Treatment ranges from transfusions and growth factors to hypomethylating drugs and, for the fit, transplant."}],"tags":[]},"sortKeys":{"year":0}},{"id":"inventisbio","name":"InventisBio","tldr":"InventisBio developed garsorasib, one of the two KRAS G12C pills approved in China in 2024, and the third-generation EGFR inhibitor befotertinib.","route":"/companies/inventisbio/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=inventisbio.com&sz=128","avatar":"org","sub":"Shanghai, CN · 688382.SS","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"iparomlimab-tuvonralimab","name":"Iparomlimab and tuvonralimab","tldr":"QL1706 is Qilu Pharmaceutical's PD-1 plus CTLA-4 antibody mixture, approved in China in 2024 for recurrent or metastatic cervical cancer after platinum chemotherapy.","route":"/drugs/iparomlimab-tuvonralimab/","status":"approved","kind":"drug","molecule":"iparomlimab-tuvonralimab","modality":"Bifunctional antibody mixture: anti-PD-1 and anti-CTLA-4","sub":"QL1706","facets":{"kind":["Treatment"],"cancers":["Cervical cancer"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."}],"year":{"facet":"year","value":"2024"},"tags":[{"label":"nmpa-approved","href":"/tagged/nmpa-approved/","tip":"Every record tagged nmpa-approved."}]},"sortKeys":{"year":2024}},{"id":"iruplinalkib","name":"Iruplinalkib","tldr":"Iruplinalkib is Qilu Pharmaceutical's second-generation ALK inhibitor, approved in China in 2023 for ALK-positive non-small-cell lung cancer after crizotinib and in 2024 as first-line treatment.","route":"/drugs/iruplinalkib/","status":"approved","kind":"drug","molecule":"iruplinalkib","modality":"Oral ALK and ROS1 tyrosine kinase inhibitor","sub":"WX-0593","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","ALK-positive non-small-cell lung cancer"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"ALK-positive non-small-cell lung cancer","href":"/cancers/alk-positive-nsclc/","tip":"ALK-positive lung cancer is driven by a fused ALK gene and is treated with a pill from the start. The newest inhibitors keep the disease under control for years, with lorlatinib holding six in ten patients progression-free at five years, and two years of alectinib after surgery cuts recurrence by three quarters."}],"year":{"facet":"year","value":"2023"},"tags":[{"label":"nmpa-approved","href":"/tagged/nmpa-approved/","tip":"Every record tagged nmpa-approved."}]},"sortKeys":{"year":2023}},{"id":"jacobio-pharmaceuticals","name":"Jacobio Pharmaceuticals","tldr":"Jacobio Pharmaceuticals is a Chinese developer in Beijing that sponsors 6 registered cancer trials of JAB-30355 and JAB-2485.","route":"/companies/jacobio-pharmaceuticals/","kind":"company","logo":"/logos/jacobio-pharmaceuticals.png","avatar":"org","sub":"Beijing, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"fan-jia","name":"Jia Fan","tldr":"Jia Fan leads one of the world's busiest liver cancer surgery and transplant programmes and the proteogenomic studies that mapped how hepatitis B-related liver cancer differs at the molecular level.","route":"/people/fan-jia/","kind":"person","round":true,"avatar":"person","sub":"President, Zhongshan Hospital, Fudan University; Liver Cancer Institute · Zhongshan Hospital, Fudan University","facets":{"kind":["Person"],"cancers":["Hepatocellular carcinoma","Biliary tract cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"clinician-scientist","href":"/tagged/clinician-scientist/","tip":"Every record tagged clinician-scientist."},{"label":"liver cancer","href":"/tagged/liver-cancer/","tip":"Every record tagged liver cancer."},{"label":"surgical oncology","href":"/tagged/surgical-oncology/","tip":"Every record tagged surgical oncology."}]},"sortKeys":{"year":0}},{"id":"jiangsu-cancer-hospital","name":"Jiangsu Cancer Hospital","tldr":"Jiangsu Cancer Hospital in Nanjing is a large provincial cancer centre and a frequent lead site for Chinese oesophageal, lung and gastric cancer trials.","route":"/institutions/jiangsu-cancer-hospital/","kind":"institution","logo":"https://www.google.com/s2/favicons?domain=jszlyy.com.cn&sz=128","avatar":"org","sub":"Nanjing Medical University · Nanjing, CN","facets":{"kind":["Institution"],"cancers":["Oesophageal cancer","Non-small-cell lung cancer","Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Institution","tip":"The centres and universities that matter, mapped and ranked."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hengrui","name":"Jiangsu Hengrui Pharmaceuticals","tldr":"Jiangsu Hengrui is China's largest oncology pharma, maker of pyrotinib and the HER2 ADC trastuzumab rezetecan, and one of the biggest out-licensers of Chinese assets.","route":"/companies/hengrui/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=hengrui.com&sz=128","avatar":"org","sub":"Lianyungang, CN · 600276.SS","facets":{"kind":["Company"],"cancers":["HER2-positive breast cancer","Non-small-cell lung cancer","Hepatocellular carcinoma","Small-cell lung cancer","HR-positive / HER2-negative breast cancer","Oesophageal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"xu-jianming","name":"Jianming Xu","tldr":"Jianming Xu led the Chinese stomach cancer trials of sintilimab, the ADC disitamab vedotin and other domestic drugs, in the country with the most stomach cancer patients.","route":"/people/xu-jianming/","kind":"person","round":true,"avatar":"person","sub":"Professor of Gastrointestinal Oncology; Fifth Medical Center, Chinese PLA General Hospital, Beijing · Chinese PLA General Hospital","facets":{"kind":["Person"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"jilin-cancer-hospital","name":"Jilin Cancer Hospital","tldr":"Jilin Cancer Hospital in Changchun is the centre that led China's small cell lung cancer immunotherapy trials, including ASTRUM-005 and CAPSTONE-1.","route":"/institutions/jilin-cancer-hospital/","kind":"institution","logo":"/logos/jilin-cancer-hospital.jpg","avatar":"org","sub":"Changchun, CN","facets":{"kind":["Institution"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Institution","tip":"The centres and universities that matter, mapped and ranked."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"oyler-john","name":"John Oyler","tldr":"John Oyler co-founded BeiGene in Beijing in 2010 and built it into the first China-born biotech to run global trials, win FDA approvals and out-sell Western rivals with zanubrutinib.","route":"/people/oyler-john/","kind":"person","round":true,"avatar":"person","sub":"Co-founder, Chairman and CEO, BeOne Medicines (formerly BeiGene)","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"guo-jun","name":"Jun Guo","tldr":"Jun Guo built China's melanoma programme around the acral and mucosal subtypes common in Asia, and led the trials that made toripalimab the first domestic PD-1 antibody approved.","route":"/people/guo-jun/","kind":"person","round":true,"avatar":"person","sub":"Professor; Department of Renal Cancer and Melanoma, Peking University Cancer Hospital · Peking University Cancer Hospital","facets":{"kind":["Person"],"cancers":["Melanoma","Renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"jupiter-06","name":"JUPITER-06","tldr":"The trial that added toripalimab to chemotherapy for oesophageal cancer in China and showed a survival gain regardless of PD-L1 level.","route":"/trials/jupiter-06/","status":"positive","kind":"trial","cancerIcon":"esophageal","sub":"NCT03829969","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"juventas-cell-therapy","name":"Juventas Cell Therapy","tldr":"Juventas Cell Therapy in Tianjin developed inaticabtagene autoleucel, the first CAR-T approved in China for leukaemia (2023).","route":"/companies/juventas-cell-therapy/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=juventascell.com&sz=128","avatar":"org","sub":"Tianjin, China, CN","facets":{"kind":["Company"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"jw-therapeutics","name":"JW Therapeutics","tldr":"JW Therapeutics, a Juno and WuXi AppTec joint venture, made relma-cel, the first CAR-T developed and manufactured in China to be approved.","route":"/companies/jw-therapeutics/","kind":"company","logo":"/logos/jw-therapeutics.png","avatar":"org","sub":"Shanghai, CN · 2126.HK","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"legend-2","name":"LEGEND-2","tldr":"The small Chinese trial whose startling response rates at ASCO 2017 drew Johnson and Johnson to Legend Biotech and became the myeloma CAR-T Carvykti.","route":"/trials/legend-2/","status":"positive","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT03090659","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":["2017"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"year":{"facet":"year","value":"2017"},"tags":[]},"sortKeys":{"year":2017}},{"id":"linperlisib","name":"Linperlisib","tldr":"Linperlisib is Shanghai Yingli's PI3K-delta inhibitor, approved in China in 2022 for relapsed or refractory follicular lymphoma after two or more lines.","route":"/drugs/linperlisib/","status":"approved","kind":"drug","molecule":"linperlisib","modality":"Oral PI3K-delta inhibitor","sub":"YY-20394","facets":{"kind":["Treatment"],"cancers":["Follicular lymphoma"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."}],"year":{"facet":"year","value":"2022"},"tags":[{"label":"nmpa-approved","href":"/tagged/nmpa-approved/","tip":"Every record tagged nmpa-approved."}]},"sortKeys":{"year":2022}},{"id":"lummicar-1","name":"LUMMICAR STUDY 1","tldr":"The Chinese trial behind zevor-cel's approval for multiple myeloma, showing deep and lasting responses with a fully human BCMA CAR-T.","route":"/trials/lummicar-1/","status":"positive","kind":"trial","cancerIcon":"multiple-myeloma","sub":"NCT03975907","facets":{"kind":["Trial"],"cancers":["Multiple myeloma"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"mecapegfilgrastim","name":"Mecapegfilgrastim","tldr":"Mecapegfilgrastim is Hengrui's long-acting G-CSF, approved in China in 2018 to prevent chemotherapy-induced neutropenia.","route":"/drugs/mecapegfilgrastim/","status":"approved","kind":"drug","molecule":"mecapegfilgrastim","modality":"Long-acting granulocyte colony-stimulating factor (growth factor support)","sub":"HHPG-19K","facets":{"kind":["Treatment"],"cancers":[],"year":["2018"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"year":{"facet":"year","value":"2018"},"tags":[{"label":"nmpa-approved","href":"/tagged/nmpa-approved/","tip":"Every record tagged nmpa-approved."}]},"sortKeys":{"year":2018}},{"id":"yu-michael","name":"Michael Yu (Yu De-Chao)","tldr":"Michael Yu founded Innovent in Suzhou in 2011 and made sintilimab one of China's best-selling cancer drugs before turning the company into a supplier of new medicines to Roche and Takeda.","route":"/people/yu-michael/","kind":"person","round":true,"avatar":"person","sub":"Founder, Chairman and CEO, Innovent Biologics","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"xia-michelle","name":"Michelle Xia (Xia Yu)","tldr":"Michelle Xia founded Akeso, the Zhongshan company whose bispecific antibody ivonescimab was the first drug to beat pembrolizumab in a head-to-head trial.","route":"/people/xia-michelle/","kind":"person","round":true,"avatar":"person","sub":"Founder, Chairwoman and CEO, Akeso","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"nanjing-immunophage-biotech","name":"Nanjing Immunophage Biotech","tldr":"Nanjing Immunophage Biotech is a Chinese developer in Nanjing that sponsors 2 registered cancer trials of IPG1094 and IPG7236.","route":"/companies/nanjing-immunophage-biotech/","kind":"company","avatar":"org","sub":"Nanjing, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"ncc-china","name":"National Cancer Center of China","tldr":"The National Cancer Center is the body that counts China's cancers, sets national screening and quality programmes and publishes the country's official cancer statistics.","route":"/institutions/ncc-china/","kind":"institution","logo":"https://www.google.com/s2/favicons?domain=chinancpcn.org.cn&sz=128","avatar":"org","sub":"Beijing, CN","facets":{"kind":["Institution"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Institution","tip":"The centres and universities that matter, mapped and ranked."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"nhsa","name":"National Healthcare Security Administration","tldr":"The NHSA runs China's public health insurance and negotiates once a year which new cancer drugs are reimbursed, and at what price, through the National Reimbursement Drug List.","route":"/institutions/nhsa/","kind":"institution","logo":"https://www.google.com/s2/favicons?domain=nhsa.gov.cn&sz=128","avatar":"org","sub":"Beijing, CN","facets":{"kind":["Institution"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Institution","tip":"The centres and universities that matter, mapped and ranked."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"orelabrutinib","name":"Orelabrutinib","tldr":"Orelabrutinib is InnoCare's BTK-blocking pill for chronic lymphocytic leukaemia and mantle cell lymphoma, approved in China in 2020.","route":"/drugs/orelabrutinib/","status":"approved","kind":"drug","molecule":"orelabrutinib","modality":"Small-molecule covalent BTK inhibitor (second generation)","sub":"Yinuokai · ICP-022","facets":{"kind":["Treatment"],"cancers":["Chronic lymphocytic leukaemia","Mantle cell lymphoma"],"year":["2020"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Mantle cell lymphoma","href":"/cancers/mantle-cell-lymphoma/","tip":"An uncommon B-cell lymphoma driven by cyclin D1 that used to behave badly in almost everyone. BTK inhibitors, CAR-T and now BCL2 drugs have changed it from chemotherapy-plus-transplant to targeted combinations."}],"year":{"facet":"year","value":"2020"},"tags":[]},"sortKeys":{"year":2020}},{"id":"orient-11","name":"ORIENT-11","tldr":"The trial that made sintilimab a first-line lung cancer treatment in China, and the one the FDA later refused to accept as evidence for US patients.","route":"/trials/orient-11/","status":"positive","kind":"trial","cancerIcon":"nsclc","sub":"NCT03607539","facets":{"kind":["Trial"],"cancers":["Non-small-cell lung cancer"],"year":["2020"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2020"},"tags":[]},"sortKeys":{"year":2020}},{"id":"orient-16","name":"ORIENT-16","tldr":"The Chinese stomach cancer trial that showed adding sintilimab to chemotherapy helps patients live longer, especially when the tumour expresses PD-L1.","route":"/trials/orient-16/","status":"positive","kind":"trial","cancerIcon":"gastric","sub":"NCT03745170","facets":{"kind":["Trial"],"cancers":["Gastric & gastro-oesophageal junction cancer"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"year":{"facet":"year","value":"2023"},"tags":[]},"sortKeys":{"year":2023}},{"id":"orient-32","name":"ORIENT-32","tldr":"A Chinese trial showing that a PD-1 antibody plus a bevacizumab copy extends life in liver cancer, mirroring the global IMbrave150 result in a hepatitis B population.","route":"/trials/orient-32/","status":"positive","kind":"trial","cancerIcon":"hcc","sub":"NCT03794440","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"pku-peoples-hospital","name":"Peking University People's Hospital","tldr":"Peking University People's Hospital is the world's largest haploidentical stem cell transplant centre and the home of the Beijing Protocol that lets almost any patient find a donor.","route":"/institutions/pku-peoples-hospital/","kind":"institution","logo":"https://www.google.com/s2/favicons?domain=pkuph.cn&sz=128","avatar":"org","sub":"Peking University · Beijing, CN","facets":{"kind":["Institution"],"cancers":["Acute myeloid leukaemia","Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Institution","tip":"The centres and universities that matter, mapped and ranked."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sun-piaoyang","name":"Piaoyang Sun","tldr":"Piaoyang Sun turned a small Lianyungang generics factory into Hengrui, China's largest originator drug company and the source of camrelizumab, apatinib and a dozen other approved cancer drugs.","route":"/people/sun-piaoyang/","kind":"person","round":true,"avatar":"person","sub":"Chairman, Jiangsu Hengrui Pharmaceuticals","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"qing-zhou","name":"Qing Zhou","tldr":"Chinese thoracic oncologist behind HARMONi-2, where the PD-1/VEGF bispecific ivonescimab beat pembrolizumab head to head.","route":"/people/qing-zhou/","kind":"person","round":true,"avatar":"person","sub":"Chief of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital · Guangdong Provincial People's Hospital","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[{"label":"lung","href":"/tagged/lung/","tip":"Every record tagged lung."},{"label":"bispecific","href":"/tagged/bispecific/","tip":"Every record tagged bispecific."}]},"sortKeys":{"year":0}},{"id":"rationale-302","name":"RATIONALE-302","tldr":"The global trial in which tislelizumab beat chemotherapy for oesophageal cancer that had progressed after first treatment, which carried it to approval in the US, Europe and Japan.","route":"/trials/rationale-302/","status":"positive","kind":"trial","cancerIcon":"esophageal","sub":"NCT03430843","facets":{"kind":["Trial"],"cancers":["Oesophageal cancer"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"recombinant-human-endostatin","name":"Recombinant human endostatin","tldr":"Endostar is Simcere's recombinant endostatin, approved in China in 2005 with chemotherapy for advanced non-small-cell lung cancer, one of the first angiogenesis inhibitors approved anywhere.","route":"/drugs/recombinant-human-endostatin/","status":"approved","kind":"drug","molecule":"recombinant-human-endostatin","modality":"Recombinant angiogenesis inhibitor protein","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":["2005"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2005"},"tags":[{"label":"nmpa-approved","href":"/tagged/nmpa-approved/","tip":"Every record tagged nmpa-approved."}]},"sortKeys":{"year":2005}},{"id":"reliance","name":"RELIANCE","tldr":"The trial that made relma-cel the first CAR-T developed and manufactured in China to be approved, with three quarters of patients responding.","route":"/trials/reliance/","status":"positive","kind":"trial","cancerIcon":"dlbcl","facets":{"kind":["Trial"],"cancers":["Diffuse large B-cell lymphoma"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"relmacabtagene-autoleucel","name":"Relmacabtagene autoleucel","tldr":"Relma-cel was the first CAR-T therapy developed and made in China to be approved, for large B-cell lymphoma that has come back after two treatments.","route":"/drugs/relmacabtagene-autoleucel/","status":"approved","kind":"drug","molecule":"relmacabtagene-autoleucel","modality":"Cell therapy (autologous CD19 CAR-T, 4-1BB)","sub":"Carteyva · relma-cel, JWCAR029","facets":{"kind":["Treatment"],"cancers":["Diffuse large B-cell lymphoma","Follicular lymphoma"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"renji-hospital","name":"Renji Hospital, Shanghai Jiao Tong University","tldr":"Renji Hospital and the Shanghai Cancer Institute on its campus are where CARsgen's solid-tumour CAR-T work began, including the Claudin 18.2 CAR-T satri-cel for stomach cancer.","route":"/institutions/renji-hospital/","kind":"institution","logo":"https://www.google.com/s2/favicons?domain=renji.com&sz=128","avatar":"org","sub":"Shanghai Jiao Tong University · Shanghai, CN","facets":{"kind":["Institution"],"cancers":["Gastric & gastro-oesophageal junction cancer","Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Institution","tip":"The centres and universities that matter, mapped and ranked."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"rivoceranib","name":"Rivoceranib (apatinib)","tldr":"Apatinib, sold as rivoceranib outside China, was the first pill of its kind approved for stomach cancer and is now the partner of camrelizumab in first-line liver cancer.","route":"/drugs/rivoceranib/","status":"approved","kind":"drug","molecule":"rivoceranib","modality":"Small-molecule VEGFR2 TKI","sub":"Aitan · apatinib, YN968D1","facets":{"kind":["Treatment"],"cancers":["Gastric & gastro-oesophageal junction cancer","Hepatocellular carcinoma"],"year":["2014"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"year":{"facet":"year","value":"2014"},"tags":[]},"sortKeys":{"year":2014}},{"id":"chen-saijuan","name":"Saijuan Chen","tldr":"Saijuan Chen helped turn acute promyelocytic leukaemia from one of the deadliest leukaemias into one of the most curable, by showing how retinoic acid and arsenic act and combining them.","route":"/people/chen-saijuan/","kind":"person","round":true,"avatar":"person","sub":"Professor; Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine · Ruijin Hospital, Shanghai Jiao Tong University","facets":{"kind":["Person"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"du-samantha","name":"Samantha Du (Du Ying)","tldr":"Samantha Du founded Zai Lab in 2014 to license Western cancer drugs for China, bringing niraparib, zanidatamab and Tumour Treating Fields to Chinese patients years earlier than they would otherwise have arrived.","route":"/people/du-samantha/","kind":"person","round":true,"avatar":"person","sub":"Founder, Chairperson and CEO, Zai Lab","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"savolitinib","name":"Savolitinib","tldr":"Savolitinib is a Chinese-discovered pill that blocks the MET growth signal, approved in China for lung cancers with a MET exon 14 mutation and being tested worldwide with osimertinib.","route":"/drugs/savolitinib/","status":"approved","kind":"drug","molecule":"savolitinib","modality":"Small-molecule selective MET TKI","sub":"Orpathys · HMPL-504, AZD6094, volitinib","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Renal cell carcinoma","Gastric & gastro-oesophageal junction cancer","Papillary renal cell carcinoma","MET exon 14 and MET-amplified non-small-cell lung cancer","EGFR-mutated non-small-cell lung cancer"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Papillary renal cell carcinoma","href":"/cancers/papillary-rcc/","tip":"Papillary kidney cancer is the second commonest type and does not share the VHL biology of clear cell cancer, so the drugs work differently: the MET-targeting drug cabozantinib beat sunitinib in the first trial run just for this disease, and two hereditary syndromes account for some cases."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"shandong-new-time-pharmaceutical","name":"Shandong New Time Pharmaceutical","tldr":"Shandong New Time Pharmaceutical is a Chinese developer in Shandong that sponsors 3 registered cancer trials of F182112 and F182112 single-agent.","route":"/companies/shandong-new-time-pharmaceutical/","kind":"company","avatar":"org","sub":"Shandong, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"allist","name":"Shanghai Allist Pharmaceuticals","tldr":"Allist is the single-product lung cancer company behind furmonertinib, China's other third-generation EGFR pill, partnered with ArriVent for the rest of the world.","route":"/companies/allist/","kind":"company","logo":"/logos/allist.png","avatar":"org","sub":"Shanghai, CN · 688578.SS","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"henlius","name":"Shanghai Henlius Biotech","tldr":"Chinese biosimilar and biologics company whose PD-1 antibody serplulimab is approved in China and Europe for small-cell lung cancer.","route":"/companies/henlius/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=henlius.com&sz=128","avatar":"org","sub":"Shanghai, CN · 2696.HK","facets":{"kind":["Company"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"junshi","name":"Shanghai Junshi Biosciences","tldr":"Junshi developed toripalimab, the first Chinese PD-1 antibody approved in China (2018) and the first approved by the FDA (2023, nasopharyngeal cancer).","route":"/companies/junshi/","kind":"company","logo":"/logos/junshi.png","avatar":"org","sub":"Shanghai, CN · 1877.HK / 688180.SS","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"shanghai-sunway-biotech","name":"Shanghai Sunway Biotech","tldr":"Shanghai Sunway Biotech makes Oncorine (H101), the oncolytic adenovirus approved in China in 2005, the first oncolytic virus approved anywhere.","route":"/companies/shanghai-sunway-biotech/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=sunwaybio.com.cn&sz=128","avatar":"org","sub":"Shanghai, China, CN","facets":{"kind":["Company"],"cancers":["Nasopharyngeal carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Nasopharyngeal carcinoma","href":"/cancers/nasopharyngeal/","tip":"A cancer at the back of the nose caused largely by the Epstein-Barr virus and common in southern China and Southeast Asia. Radiation cures most early cases; adding chemotherapy and, recently, PD-1 immunotherapy has improved outcomes in advanced disease, and a blood test for viral DNA can detect it early."}],"tags":[]},"sortKeys":{"year":0}},{"id":"shanghai-yingli","name":"Shanghai Yingli Pharmaceutical","tldr":"Shanghai Yingli Pharmaceutical developed linperlisib, the PI3K-delta inhibitor approved in China in 2022 for relapsed follicular lymphoma.","route":"/companies/shanghai-yingli/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=yingli-pharma.com&sz=128","avatar":"org","sub":"Shanghai, China, CN","facets":{"kind":["Company"],"cancers":["Follicular lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."}],"tags":[]},"sortKeys":{"year":0}},{"id":"qin-shukui","name":"Shukui Qin","tldr":"Shukui Qin has led most of the Chinese liver cancer trials of the past decade, including the ones that put camrelizumab plus rivoceranib and donafenib into first-line use.","route":"/people/qin-shukui/","kind":"person","round":true,"avatar":"person","sub":"Professor of Medical Oncology; Nanjing Tianyinshan Hospital, China Pharmaceutical University (formerly Jinling Hospital, Nanjing)","facets":{"kind":["Person"],"cancers":["Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sichuan-cancer-hospital","name":"Sichuan Cancer Hospital","tldr":"Sichuan Cancer Hospital in Chengdu is a large provincial cancer centre known for oesophageal and head and neck cancer radiotherapy and a partner of the city's ADC companies.","route":"/institutions/sichuan-cancer-hospital/","kind":"institution","logo":"https://www.google.com/s2/favicons?domain=sichuancancer.org&sz=128","avatar":"org","sub":"Chengdu, CN","facets":{"kind":["Institution"],"cancers":["Oesophageal cancer","Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Institution","tip":"The centres and universities that matter, mapped and ranked."},"cancers":[{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sino-biopharm","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","tldr":"Sino Biopharm, through Chia Tai Tianqing, sells anlotinib, one of China's biggest cancer drugs, and acquired LaNova Medicines to add bispecific antibodies and ADCs.","route":"/companies/sino-biopharm/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=sinobiopharm.com&sz=128","avatar":"org","sub":"Hong Kong / Nanjing, CN · 1177.HK","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"sintilimab","name":"Sintilimab","tldr":"Sintilimab is Innovent's PD-1 antibody, approved in China since 2018 for Hodgkin lymphoma and then, on the ORIENT trials, for first-line lung, liver, oesophageal and stomach cancer. In 2022 the FDA rejected its lung cancer application because a China-only trial against chemotherapy did not fit US practice, defining the agency's stance on single-country data.","route":"/drugs/sintilimab/","status":"approved","kind":"drug","molecule":"sintilimab","modality":"Monoclonal antibody (anti-PD-1, IgG4)","sub":"Tyvyt · IBI308","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Hepatocellular carcinoma","Oesophageal cancer","Gastric & gastro-oesophageal junction cancer","Hodgkin lymphoma"],"year":["2018"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"year":{"facet":"year","value":"2018"},"tags":[]},"sortKeys":{"year":2018}},{"id":"sugemalimab","name":"Sugemalimab","tldr":"Sugemalimab is CStone's PD-L1 antibody, approved in China for first-line lung cancer with chemotherapy and after chemoradiotherapy in stage III disease, and the first China-developed PD-L1 antibody to win European approval.","route":"/drugs/sugemalimab/","status":"approved","kind":"drug","molecule":"sugemalimab","modality":"Monoclonal antibody (anti-PD-L1, fully human IgG4)","sub":"Cejemly · CS1001","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Peripheral T-cell lymphomas"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"surufatinib","name":"Surufatinib","tldr":"Surufatinib is HUTCHMED's angio-immuno kinase inhibitor, approved in China in 2020 for non-pancreatic and in 2021 for pancreatic neuroendocrine tumours.","route":"/drugs/surufatinib/","status":"approved","kind":"drug","molecule":"surufatinib","modality":"Oral VEGFR, FGFR1 and CSF1R tyrosine kinase inhibitor","sub":"HMPL-012","facets":{"kind":["Treatment"],"cancers":["Neuroendocrine tumours"],"year":["2020"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Neuroendocrine tumours","href":"/cancers/neuroendocrine/","tip":"A family of usually slow-growing tumours that start in hormone-producing cells of the gut, pancreas and lungs. They pioneered the idea of using the same molecule to see a tumour on a scan and then to treat it with radiation."}],"year":{"facet":"year","value":"2020"},"tags":[{"label":"nmpa-approved","href":"/tagged/nmpa-approved/","tip":"Every record tagged nmpa-approved."}]},"sortKeys":{"year":2020}},{"id":"zelgen","name":"Suzhou Zelgen Biopharmaceuticals","tldr":"Zelgen developed donafenib, the deuterated sorafenib that beat the original in first-line liver cancer and was approved in China in 2021.","route":"/companies/zelgen/","kind":"company","logo":"/logos/zelgen.png","avatar":"org","sub":"Suzhou, CN · 688266.SS","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"tj-biopharma","name":"TJ Biopharma","tldr":"TJ Biopharma is a Chinese developer in Shanghai that sponsors 2 registered cancer trials of Uliledlimab and Sintilimab.","route":"/companies/tj-biopharma/","kind":"company","logo":"/logos/tj-biopharma.png","avatar":"org","sub":"Shanghai, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"tucidinostat","name":"Tucidinostat (chidamide)","tldr":"Chidamide, approved in 2014, was the first epigenetic cancer drug invented in China and the first oral drug of its kind anywhere, used for T-cell lymphoma and, with hormone therapy, for breast cancer.","route":"/drugs/tucidinostat/","status":"approved","kind":"drug","molecule":"tucidinostat","modality":"Small-molecule oral subtype-selective HDAC inhibitor","sub":"Epidaza · chidamide, HBI-8000, CS055","facets":{"kind":["Treatment"],"cancers":["Peripheral T-cell lymphomas","HR-positive / HER2-negative breast cancer"],"year":["2014"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Peripheral T-cell lymphomas","href":"/cancers/peripheral-t-cell-lymphoma/","tip":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"year":{"facet":"year","value":"2014"},"tags":[]},"sortKeys":{"year":2014}},{"id":"utidelone","name":"Utidelone","tldr":"Utidelone is Biostar Pharmaceuticals' epothilone chemotherapy, approved in China in 2021 with capecitabine for advanced breast cancer after anthracyclines and taxanes.","route":"/drugs/utidelone/","status":"approved","kind":"drug","molecule":"utidelone","modality":"Epothilone analogue, microtubule-stabilising cytotoxic chemotherapy","sub":"UTD1","facets":{"kind":["Treatment"],"cancers":[],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"year":{"facet":"year","value":"2021"},"tags":[{"label":"nmpa-approved","href":"/tagged/nmpa-approved/","tip":"Every record tagged nmpa-approved."}]},"sortKeys":{"year":2021}},{"id":"vorolanib","name":"Vorolanib","tldr":"Vorolanib is Betta Pharmaceuticals' oral VEGFR and PDGFR inhibitor, approved in China in 2023 with everolimus for advanced kidney cancer after a first kinase inhibitor has failed.","route":"/drugs/vorolanib/","status":"approved","kind":"drug","molecule":"vorolanib","modality":"Oral multi-target VEGFR and PDGFR tyrosine kinase inhibitor","sub":"X-82","facets":{"kind":["Treatment"],"cancers":["Renal cell carcinoma"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"year":{"facet":"year","value":"2023"},"tags":[{"label":"nmpa-approved","href":"/tagged/nmpa-approved/","tip":"Every record tagged nmpa-approved."}]},"sortKeys":{"year":2023}},{"id":"su-weiguo","name":"Weiguo Su","tldr":"Weiguo Su led the Shanghai chemistry that produced fruquintinib, savolitinib and surufatinib, three Chinese-discovered cancer pills approved at home and, for fruquintinib, in the US.","route":"/people/su-weiguo/","kind":"person","round":true,"avatar":"person","sub":"CEO and Chief Scientific Officer, Hutchmed","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"wuxi-apptec","name":"WuXi AppTec","tldr":"WuXi AppTec is the contract research and manufacturing giant that makes small molecules, including ADC payloads and linkers, for much of the global cancer pipeline, and the target of the US BIOSECURE Act.","route":"/companies/wuxi-apptec/","kind":"company","logo":"/logos/wuxi-apptec.svg","avatar":"org","sub":"Shanghai, CN · 603259.SS / 2359.HK","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"wuxi-biologics","name":"WuXi Biologics","tldr":"WuXi Biologics develops and manufactures antibodies for hundreds of clients worldwide, and its WuXi XDC unit is the largest contract maker of antibody-drug conjugates.","route":"/companies/wuxi-biologics/","kind":"company","logo":"/logos/wuxi-biologics.jpg","avatar":"org","sub":"Wuxi / Shanghai, CN · 2269.HK","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"huang-xiaojun","name":"Xiaojun Huang","tldr":"Xiaojun Huang built the Beijing Protocol for stem cell transplants from half-matched family donors, which means almost every Chinese leukaemia patient can now find a donor.","route":"/people/huang-xiaojun/","kind":"person","round":true,"avatar":"person","sub":"Director, Peking University Institute of Hematology; Peking University People's Hospital · Peking University People's Hospital","facets":{"kind":["Person"],"cancers":["Acute myeloid leukaemia","Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"cheng-ying","name":"Ying Cheng","tldr":"Ying Cheng has led most of the Chinese small cell lung cancer immunotherapy trials, including ASTRUM-005 and CAPSTONE-1.","route":"/people/cheng-ying/","kind":"person","round":true,"avatar":"person","sub":"Professor and President, Jilin Cancer Hospital, Changchun · Jilin Cancer Hospital","facets":{"kind":["Person"],"cancers":["Small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer that responds to chemotherapy then relapses quickly. After 30 years without progress, T-cell engagers and ADCs are finally moving the needle."}],"tags":[]},"sortKeys":{"year":0}},{"id":"zai-lab","name":"Zai Lab","tldr":"Zai Lab is the in-licensing pioneer that brings Western cancer drugs to China (niraparib, zanidatamab, repotrectinib, Tumour Treating Fields) and now exports its own bispecific and ADC assets.","route":"/companies/zai-lab/","kind":"company","logo":"/logos/zai-lab.png","avatar":"org","sub":"Shanghai / Cambridge, MA, CN · ZLAB / 9688.HK","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"zevorcabtagene-autoleucel","name":"Zevorcabtagene autoleucel","tldr":"Zevor-cel is CARsgen's myeloma CAR-T, approved in China in 2024 for patients whose disease has come back after three or more treatments.","route":"/drugs/zevorcabtagene-autoleucel/","status":"approved","kind":"drug","molecule":"zevorcabtagene-autoleucel","modality":"Cell therapy (autologous BCMA CAR-T, fully human binder)","sub":"Saikaize · zevor-cel, CT053","facets":{"kind":["Treatment"],"cancers":["Multiple myeloma"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"zgdh3","name":"ZGDH3 (donafenib vs sorafenib)","tldr":"The first trial in which a new pill beat sorafenib on survival in liver cancer, with a Chinese deuterated redesign of sorafenib itself.","route":"/trials/zgdh3/","status":"positive","kind":"trial","cancerIcon":"hcc","sub":"NCT02645981","facets":{"kind":["Trial"],"cancers":["Hepatocellular carcinoma"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Trial","tip":"Landmark and current trials that define the standard of care."},"cancers":[{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"chen-zhu","name":"Zhu Chen","tldr":"Zhu Chen, a leukaemia scientist who became China's health minister, co-developed the retinoic acid plus arsenic treatment that cures most acute promyelocytic leukaemia and then reformed the health system that pays for it.","route":"/people/chen-zhu/","kind":"person","round":true,"avatar":"person","sub":"Professor, Shanghai Institute of Hematology, Ruijin Hospital; former Minister of Health of China (2007 to 2013) · Ruijin Hospital, Shanghai Jiao Tong University","facets":{"kind":["Person"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"zhuhai-yufan-biotechnologies","name":"Zhuhai Yufan Biotechnologies","tldr":"Zhuhai Yufan Biotechnologies is a Chinese developer in Zhuhai that sponsors 2 registered cancer trials of PRJ1-3024.","route":"/companies/zhuhai-yufan-biotechnologies/","kind":"company","avatar":"org","sub":"Zhuhai, China, CN","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[{"label":"registry-only","href":"/tagged/registry-only/","tip":"Every record tagged registry-only."}]},"sortKeys":{"year":0}},{"id":"li-zonghai","name":"Zonghai Li","tldr":"Zonghai Li moved CAR-T therapy from blood cancers into stomach cancer, founding CARsgen and developing satri-cel, the first CAR-T approved for a solid tumour.","route":"/people/li-zonghai/","kind":"person","round":true,"avatar":"person","sub":"Founder, Chairman and CEO, CARsgen Therapeutics; Professor, Shanghai Cancer Institute, Renji Hospital · Renji Hospital, Shanghai Jiao Tong University","facets":{"kind":["Person"],"cancers":["Gastric & gastro-oesophageal junction cancer","Hepatocellular carcinoma","Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}}]